NEWS & EVENTS
Inimmune is a collaborator in the University of Montana's effort to bring opioid vaccines to clinical trials.
(Missoula, MT) Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A...
Inimmune lands the an $22 million dollar investment, let by Two Bear Capital. The investment is believed to be largest Series A funding in state history; Inimmune, which is based in Missoula,...
Montana Biotech Company Receives $2 M Small Business Innovation Research Grant to Advance Vaccine Technologies
Inimmune Corporation, a biotechnology company located in Missoula, MT, was recently awarded a $2 M grant from the National Institute for Allergy and Infectious Diseases (NIAID) under its Small...
Inimmune Corporation is joining in on efforts to develop a COVID-19 vaccine with a nasal spray that could offer protection against coronavirus. The research efforts are in collaboration with...
The science behind the silent killer. Here is how Inimmune is developing vaccines to help solve the opioid epidemic. Read full article: Science and the Silent Killer
Bioscience research and development can unlock the economic potential of the Mountain West, providing jobs and substantial economic benefit. Read how Inimmune Corporation in Missoula, Montana...
The University of Montana is a recipient of a $3.3 million dollar contract from the National Institutes of Health to develop a vaccine to treat opioid addiction. Inimmune Corporation will be a...
Look for us at these upcoming conferences. If you are interested in scheduling a face to face meeting during one of these conferences please use the contact button
BIO International – June 2020
Smith AJ, Li Y, Bazin-Lee H, St-Jean JR, Larocque D, Baldridge J. Evaluation of novel synthetic TLR7/8 agonists as human vaccine adjuvants. Vaccine. 2016. [Epub ahead of print].
Oberoi, H.; Yorgensen, Y.; Evans, J.; Burkhart, D.; PEG modified liposomes in combination with methylglycol chitosan enhances the murine sublingual immune response to influenza vaccination Journal of Controlled Release, Vol 223, 10 Feb 2016.
Spinner, J.; Oberoi, H.; Yorgensen, Y.; Burkhart, D.; Evans, J.; Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually Vaccine, Volume 33, pages5845-5853, 2015.
Khalaf, W. S. Bowen, H.G. Bazin , K.T. Ryter, M.T. Livesay, J.R. Ward, J.T. Evans, D.A. Johnson, “Characterization of TRIF selectivity in the AGP class of lipid A mimetics: Role of secondary lipid chains”, Bioorg. Med. Chem. Lett., 25, 547-533, 2015
H.G. Bazin, Y. Li, J.K. Khalaf , S. Mwakwari, M.T. Livesay, J.T. Evans, D.A. Johnson, “Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives”, Bioorg. Med. Chem. Lett., 25, 1318-1323, 2015
H.G. Bazin, L.S. Bess, M.T. Livesay, D.A. Johnson, “Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method”, Tetrahedron Lett, 57, 2063-2066, 2016
Mwakwari, L.S. Bess, H.G. Bazin, D.A. Johnson, “Efficient tin-mediated synthesis of lysophospholipid conjugates of a TLR7/8-active imidazoquinoline”, Tetrahedron Lett, 57, 2093-2096, 2016